The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Use of pharmacogenomic modeling in pancreatic cancer for prediction of chemotherapy response and resistance.
Kenneth H. Yu
No relevant relationships to disclose
Vineet Sangar
No relevant relationships to disclose
Mark Ricigliano
Employment or Leadership Position - CellPath Therapeutics
Stock Ownership - CellPath Therapeutics
Manuel Hidalgo
Employment or Leadership Position - CellPath Therapeutics
Stock Ownership - CellPath Therapeutics
Ghassan K. Abou-Alfa
No relevant relationships to disclose
Maeve Aine Lowery
No relevant relationships to disclose
Leonard Saltz
No relevant relationships to disclose
Joseph F. Crotty
No relevant relationships to disclose
Kristen Gary
No relevant relationships to disclose
Jing Yin
Employment or Leadership Position - CellPath Therapeutics
Eun Yong Choi
Employment or Leadership Position - CellPath Therapeutics
Eileen Mary O'Reilly
No relevant relationships to disclose